OncoMatch/Clinical Trials/NCT06885034
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
Is NCT06885034 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GSK5764227 for gastrointestinal neoplasms.
Treatment: GSK5764227 — This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced colorectal cancer
Must have received at least 1 and no more than 2 lines of systemic treatment for advanced colorectal cancer (CRC), with documented progression on most recent prior line of therapy
Must have received: systemic therapy — advanced PDAC
Must have received 1 and no more than 1 line of therapy for advanced PDAC, with documented progression
Cannot have received: antibody-drug conjugate
Exception: with a Topoisomerase-1 (TOPO1)-inhibitor payload
Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload
Lab requirements
Kidney function
Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety) [excluded]
Liver function
Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice [excluded]
Cardiac function
Has severe, uncontrolled or active cardiovascular disorders; serious or poorly controlled hypertension; serious arteriovenous thromboembolic events (such as deep vein thrombosis, pulmonary embolism, etc.) within 3 months prior to the first dose
Has adequate organ function. Has severe, uncontrolled or active cardiovascular disorders. Has serious or poorly controlled hypertension. Has serious arteriovenous thromboembolic events (such as deep vein thrombosis, pulmonary embolism, etc.) within 3 months prior to the first dose. Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety). Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Los Alamitos, California
- GSK Investigational Site · Whittier, California
- GSK Investigational Site · New York, New York
- GSK Investigational Site · Durham, North Carolina
- GSK Investigational Site · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify